GlassScriptPhysician profile
Kathrine Cooper
NPI 1447487053
$828.83
in general payments reported to CMS, 2019-2025
18 companies · $38.72 in 2025
The $38.72 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.94 · 2023: $228 · 2024: $532 · 2025: $38.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $750 · Education: $47.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.34 |
| Education | $47.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $138.33 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $124.36 | 2023-2024 | Enhertu, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $97.03 | 2022-2023 | Imbruvica, Epkinly |
| Springworks Therapeutics, INC. | $66.62 | 2024-2025 | Ogsiveo |
| Glaxosmithkline, LLC. | $63.41 | 2024 | Ojjaara |
| Abbvie INC. | $40.56 | 2024 | |
| Sun Pharmaceutical Industries INC. | $39.16 | 2024 | |
| Merck Sharp & Dohme LLC | $31.67 | 2023 | Keytruda, Lynparza |
| Amgen INC. | $30.98 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $30.20 | 2023 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $27.43 | 2024 | Libtayo |
| Servier Pharmaceuticals LLC | $23.48 | 2024 | |
| Janssen Biotech, INC. | $23.43 | 2024 | Rybrevant |
| Celgene Corporation | $22.17 | 2023 | Opdualag |
| Immunocore Limited | $19.30 | 2024 | Kimmtrak |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $18.81 | 2025 | |
| Pfizer INC. | $17.90 | 2023 | |
| Array Biopharma INC | $13.99 | 2023 | Xalkori, Lorbrena, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathrine Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.